Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Violeta Rodriguez-Romero

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|October 22, 2025
Pharmacometric modeling with the zero-order holdEric L Haseltine, Violeta Rodriguez-Romero
Clinical and Translational Science|May 22, 2019
Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning TechniquesVioleta Rodriguez-Romero, Richard F Bergstrom, Brian S Decker, et al.
Clinical and Translational Science|May 3, 2021
Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trialsJagdeep T Podichetty, Rebecca M Silvola, Violeta Rodriguez-Romero, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2024
Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosisPaul McNally, Alvin Singh, Susanna A McColley, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trialJordana E Hoppe, Ajay S Kasi, Jessica E Pittman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Pharmacokinetics and Pharmacodynamics|October 22, 2025
Pharmacometric modeling with the zero-order holdEric L Haseltine, Violeta Rodriguez-Romero
Clinical and Translational Science|May 22, 2019
Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning TechniquesVioleta Rodriguez-Romero, Richard F Bergstrom, Brian S Decker, et al.
Clinical and Translational Science|May 3, 2021
Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trialsJagdeep T Podichetty, Rebecca M Silvola, Violeta Rodriguez-Romero, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2024
Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosisPaul McNally, Alvin Singh, Susanna A McColley, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trialJordana E Hoppe, Ajay S Kasi, Jessica E Pittman, et al.
Pageof 1